Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation

New England Journal of Medicine

Volumn 377, Issue 25, 2017, Pages 2433-2444

  Marty, F M ^a   Ljungman, P ^c   Chemaly, R F ^p   Maertens, J ^e   Dadwal, S S ^f   Duarte, R F ^d,h   Haider, S ⁱ   Ullmann, A J ^j   Katayama, Y ^k   Brown, J ^g   Mullane, K M ^m   Boeckh, M ⁿ   Blumberg, E A ^o   Einsele, H ^j   Snydman, D R ^b   Kanda, Y ^l   Di Nubile, M J ^p   Teal, V L ^p   Wan, H ^p   Murata, Y ^p   Kartsonis, N A ^p   Leavitt, R Y ^p   Badshah, C ^p   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^l JICHI MEDICAL UNIVERSITY   (Japan)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ USA   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOSPORIN; EVEROLIMUS; FAMCICLOVIR; LETERMOVIR; MYCOPHENOLIC ACID; PLACEBO; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALL CAUSE MORTALITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATRIAL FIBRILLATION; BONE MARROW TOXICITY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOMEGALOVIRUS INFECTION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEADACHE; HEART ATRIUM FLUTTER; HERPES VIRUS INFECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPERTENSION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RASH; RISK REDUCTION; TREATMENT DURATION; VIREMIA; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; CYTOMEGALOVIRUS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ACETATES; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; QUINAZOLINES; YOUNG ADULT;

EID: 85039768345     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1706640     Document Type: Article

References (42)

1. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982; 4: 1119-32.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-88.
3. Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis 2014; 59: 473-81.
4. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplantrelated mortality in the current era: a CIBMTR analysis. Blood 2016; 127: 2427-38.
5. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-37.
6. Hodson EM, Ladhani M, Webster AC, Strippoli GFM, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD003774.
7. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8.
8. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-84.
9. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-9.
10. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, riskadapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1687-99.
11. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057-9.
12. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-7.
13. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490-500.
14. Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis 2015; 61: 31-9.
15. Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol 2002; 12: 115-27.
16. Borst EM, Kleine-Albers J, Gabaev I, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavagepackaging and interacts with the terminase subunits pUL56 and pUL89. J Virol 2013; 87: 1720-32.
17. Weber O, Bender W, Eckenberg P, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel nonnucleosidic compound in vivo. Antiviral Res 2001; 49: 179-89.
18. Reefschlaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48: 757-67.
19. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290-7.
20. Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res 2017; 148: 1-4.
21. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884-93.
22. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370: 1781-9.
23. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-81.
24. Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 2010; 38: 1499-504.
25. Erb-Zohar K, Kropeit D, Scheuenpflug J, et al. Intravenous hydroxypropyl ?-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multipledose trial. Clin Transl Sci 2017; 10: 487-95.
26. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
27. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-26.
28. Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 2016; 213: 23-30.
29. Winston DJ, Young J-AH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study. Blood 2008; 111: 5403-10.
30. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11: 284-92.
31. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-36.
32. Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo controlled, parallelgroup phase 3 trial. Biol Blood Marrow Transplant 2016; 22: S23. abstract.
33. Marty FM, Boeckh M. Maribavir and human cytomegalovirus - what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011; 1: 555-62.
34. Razonable RR, Blumberg EA. It's not too late: a proposal to standardize the terminology of "late-onset" cytomegalovirus infection and disease in solid organ transplant recipients. Transpl Infect Dis 2015; 17: 779-84.
35. Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006; 19: 2-11.
36. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190: 177-82.
37. Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother 2015; 59: 3140-8.
38. Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Geno-and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother 2014; 58: 610-3.
39. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 2015; 59: 6588-93.
40. Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014; 27: 77-86.
41. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079-84.
42. Kimberlin DW, Jester PM, Sanchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372: 933-43.